- Home
- VRAX vs DRCT Comparison
VRAX vs DRCT Comparison
Compare VRAX & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | DRCT |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | VRAX | DRCT |
|---|---|---|
| Price | $0.15 | $0.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 19.4M | 105.0K |
| Earning Date | 06-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $34,694,000.00 |
| Revenue This Year | $217,274.83 | $5.42 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.04 |
| 52 Week High | $1.18 | $6.04 |
Technical Indicators
Market Signals| Indicator | VRAX | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 48.63 | 34.94 |
| Support Level | $0.10 | $0.52 |
| Resistance Level | $0.25 | $0.79 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 49.32 | 21.04 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.